Table 2 Predictors of good prognosis in all patients with crescentic glomerulonephritis.

From: Clinical value of urinary cytokines/chemokines as prognostic markers in patients with crescentic glomerulonephritis

Variables

Univariable

Multivariable

OR (95% CI)

P

OR (95% CI)

P

Age

1.01 (0.98–0.04)

0.66

  

Male

1.03 (0.43–2.45)

0.96

  

ln(CRP)

1.33 (1.00–1.76)

0.047

1.34 (0.94–1.90)

0.11

ln(eGFR)

3.01 (1.43–6.33)

0.004

2.74 (1.01–7.43)

0.048

ln(uPCR)

0.83 (0.28–2.45)

0.73

  

Vasculitis serology marker

0.88 (0.34–2.30)

0.79

  

Histologic features

 Normal glomeruli (%)

1.03 (1.01–1.05)

0.01

0.99 (0.97–1.03)

0.85

 Active crescents (%)

1.00 (0.98–1.02)

0.81

  

 Glomerular chronic change (%)

0.98 (0.96–0.99)

0.01

0.99 (0.96–1.01)

0.35

 Tubular chronic change

 

0.02

  

  IFTA 1 (versus IFTA 0)

0.27 (0.05–1.40)

0.12

0.24 (0.04–1.46)

0.12

  IFTA 2 (versus IFTA 0)

0.09 (0.01–0.58)

0.01

0.15 (0.02–1.23)

0.08

  IFTA 3 (versus IFTA 0)

0.07 (0.01–0.51)

0.009

0.11 (0.01–1.00)

0.05

Immunosuppressive treatment (reference: none)a

 

0.11

  

 Treatment 1

3.00 (0.21–42.63)

0.42

  

 Treatment 2

7.40 (0.77–70.77)

0.08

  

 Treatment 3

2.50 (0.21–29.26)

0.47

  

CD 45 positive cells (%)

0.99 (0.89–1.09)

0.78

  

CD 3 positive cells (%)

1.02 (0.93–1.11)

0.73

  

CD 20 positive cells (%)

0.98 (0.88–1.09)

0.71

  
  1. Logistic regression analyses were performed to determine the prognosis. Multivariable analyses were performed using variables with P < 0.1 in univariable analysis.
  2. CI, confidence interval; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IFTA, interstitial fibrosis and tubular atrophy; ref, reference; OR, odds ratio; uPCR, urine protein to creatinine ratio.
  3. aTreatment 1, 2, and 3: steroid alone, steroids with other immunosuppressants, and steroids with other immunosuppressants and plasmapheresis, respectively.
Back to article page